Breaking News

Amgen, Selexis Expand R&D License Agreement

February 20, 2013

Will evaluate the SURE CHO-M Cell Line for R&D

Amgen has expanded its R&D license agreement with Selexis SA to include an evaluation of Selexis’ SURE CHO-M Cell Line for R&D. Amgen will be able to evaluate the SURE CHO-M Cell Line in conjunction with the Selexis SUREtech Vectors for improved R&D. 
 
"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch, Ph.D., president and chief executive officer of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.